Skip To Main Content
Leon Kircik on Muck Rack

Leon Kircik

As seen in: Wiley Online Library, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, HCP Live, Dialnet - Universidad de La Rioja, MDEdge, HMP Global Learning Network, Texas Medical Center, Future Medicine, Journal of The American Academy of Dermatology (JAAD) and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Leon

Contact Leon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Highlighting New FDA Approvals for Atopic Dermatitis, with Leon H. Kircik, MD

|
By Leon Kircik
| consultantlive.com
Three recently approved topical non-steroidal treatments for patients living with atopic dermatitis were highlighted by Leon H. Kircik, MD, medical director at Skin Sciences, PLLC, at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville. In this interview with the HCPLive editorial team at RAD, Kircik highlighted these 3 additions to the atopic dermatitis treatment armamentarium. He was first asked which drugs he highlighted in his conference talk.
Open in Who Shared View Duplicates (2) Issue with article?

Abrocitinib Advantages Among Patients with Atopic Dermatitis, with Leon H. Kircik, MD

|
By Leon Kircik
| consultantlive.com
Over the course of his talk ‘Janus Kinase (JAK) Inhibitors in Atopic Dermatitis Management’ at the 2025 Revolutionizing Atopic Dermatitis (RAD) Meeting in Nashville, Leon H. Kircik, MD, highlighted a variety of useful pieces of information related to the use of Janus-Kinase (JAK) inhibitors such as abrocitinib.
Open in Who Shared View Duplicates (4) Issue with article?

Addressing JAK Inhibitor Concerns in Atopic Dermatitis, with Leon H. Kircik, MD

|
By Leon Kircik
| consultantlive.com
Leon H. Kircik, MD, spoke with the HCPLive editorial team at the 2025 Revolutionizing Atopic Dermatitis (RAD) Meeting in Nashville, TN, about the contents of his talk ‘Janus Kinase (JAK) Inhibitors in Atopic Dermatitis Management.’ Kircik—known for his work as medical director at Skin Sciences, PLLC, in Louisville, Kentucky—was asked what he sees as the biggest clinical advantage of JAK inhibitors in atopic dermatitis.
Open in Who Shared View Duplicates (2) Issue with article?
See all 65 licensed articles (92 Total)